Comparative Pharmacology
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus MYMETHAZINE FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus MYMETHAZINE FORTIS.
DIPHENHYDRAMINE HYDROCHLORIDE vs MYMETHAZINE FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
Mymethazine fortis is a phenothiazine derivative that exerts antipsychotic and antiemetic effects primarily by blocking postsynaptic dopamine D2 receptors in the mesolimbic system, as well as possessing anticholinergic, antihistaminergic, and alpha-adrenergic antagonistic properties.
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
50 mg orally every 6 hours as needed for nausea and vomiting.
None Documented
None Documented
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
Terminal elimination half-life is 15-20 hours; in renal impairment (CrCl <30 mL/min), may extend to 30-40 hours, requiring dose adjustment.
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Primarily renal (70-80% as unchanged drug and metabolites, with about 30% as unchanged); fecal (10-15%) via biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination